Laboratory Corporation of America agreed to pay $14.5 million to resolve allegations that it billed Medicare for medically unnecessary urine drug tests, the Justice Department announced on July 15, 2026. The settlement resolves claims that Labcorp, one of the nation's largest clinical diagnostics companies and a major vendor to federal health programs, routinely billed Medicare Part B for a bundled testing panel that stacked two flat-rate reimbursement codes on the same urine sample. Labcorp admitted the underlying facts as part of the agreement, though the claims remain allegations with no determination of liability.
Background
The case centers on a Labcorp product called the ToxAssure Comprehensive panel. Urine drug testing comes in two forms. Presumptive testing detects whether certain drug classes are present above set thresholds, and Medicare pays a single flat rate for it under CPT code 80307 regardless of how many drug classes a lab screens. Definitive testing identifies specific substances and their concentrations, and Medicare pays a flat rate for 22 or more drug classes under HCPCS code G0483, the highest reimbursement tier. Because both codes pay a fixed amount no matter how much testing a lab performs, a provider that runs the maximum panel on every sample captures the top payment every time. That reimbursement structure is what turned a routine diagnostic product into a False Claims Act exposure.
Key Details
According to admissions in the settlement, from January 1, 2018 through November 22, 2023 Labcorp submitted claims for presumptive and definitive urine drug testing to Medicare, some of them through the ToxAssure Comprehensive panel. That panel was a preselected mix of presumptive testing for certain substances and direct-to-definitive testing, with no prior presumptive screen, for others. Labcorp frequently ran many of these tests at once for the same patient, on the same date of service, using the same urine sample, then billed Medicare with CPT code 80307 for the presumptive testing and HCPCS code G0483 for the definitive testing. In practice, the government said, Labcorp charged Medicare for both the all-inclusive presumptive code and the highest-tier definitive code each time it performed the panel.
For several substances tested on a direct-to-definitive basis, a presumptive testing option existed, but Labcorp ran the more expensive definitive test without first performing a presumptive test to establish whether the definitive test was warranted. The United States alleged that billing the full ToxAssure Comprehensive panel this way produced medically unnecessary claims for some of the patients who received it. Labcorp represented in the agreement that it has stopped billing Medicare the 80307 and G0483 combination for beneficiaries tested with the panel.
Assistant Attorney General Brett A. Shumate of the Justice Department's Civil Division framed the conduct as a billing-integrity failure. The government expects that any testing it pays for is medically necessary and not wasteful or structured in a way that maximizes billing opportunities for providers at the expense of the federal fisc, he said, adding that the department will continue to hold providers who do otherwise accountable. U.S. Attorney Leah B. Foley for the District of Massachusetts said the settlement reflects her office's commitment to combating healthcare fraud and recovering taxpayer money, noting that Labcorp's conduct resulted in Medicare payouts for unnecessary tests. Acting Deputy Inspector General for Investigations Miranda L. Bennett of the Department of Health and Human Services Office of Inspector General said the resolution makes clear that when providers put profits before patients and ignore billing rules, the agency will act decisively.
Labcorp received settlement credit under the Justice Department's guidelines for weighing disclosure, cooperation, and remediation in False Claims Act cases, set out in Justice Manual section 4-4.112. That credit typically reduces the final settlement figure for companies that self-report, assist the investigation, and fix the underlying conduct, and Labcorp's decision to stop billing the code combination factored into the resolution. The matter was handled by the Civil Division's Commercial Litigation Branch, Fraud Section, and the U.S. Attorney's Office for the District of Massachusetts, working with HHS-OIG. Fraud Section Senior Counsel for Health Care Fraud Augustine Ripa and Assistant U.S. Attorney Abraham George handled the case, with investigative support from HHS-OIG and the FBI. The department logged the resolution as press release number 26-783.
What It Means for Contractors
The Labcorp settlement is not a traditional procurement-fraud case, but it turns on a mechanic that reaches across the federal contracting world: how a vendor codes and bills for what it delivers to the government. Any contractor that submits claims against a fixed-price schedule, a bundled rate, or a coding system faces the same exposure Labcorp did. When reimbursement is flat and volume is discretionary, structuring a standard offering to hit the top payment tier on every transaction invites a False Claims Act theory, even when each individual test or line item is real. The government's argument here was not that the tests were fake, but that defaulting to the most expensive configuration without a clinical trigger made the claims unnecessary.
The case also underscores how much the government now emphasizes False Claims Act enforcement. The Justice Department tied the resolution to the Administration's newly launched Task Force to Eliminate Fraud and National Fraud Enforcement Division, signaling that civil fraud recoveries will remain a priority tool against waste in federal programs. For contractors, the settlement is a reminder that admissions of fact, not just monetary payments, are increasingly part of these deals, and that documented cooperation and remediation carry real weight in the final number.
The practical takeaways are concrete. Contractors should confirm that any bundled or default service configuration has a defensible basis for each billed component rather than a billing-driven one, and should be able to show why a higher-tier code or rate applied to a given transaction. Compliance teams should audit recurring code combinations for patterns that maximize reimbursement regardless of need, since the same repeated pairing that flagged Labcorp is exactly what data analytics surface. And when a problem surfaces, the credit Labcorp earned shows the value of stopping the conduct, cooperating, and remediating before enforcement concludes rather than after.
